Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dyston onset of action and safety in glabellar lines
IRCT20180515039672N3Phase 4Completed
- Sponsor
- Imen Vaccine Alborz
- Start
- May 2020
- Modality
- Recombinant Proteins and Enzymes, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Onabotulinumtoxina + hydrogel in glabellar furrowing, sponsored by Imen Vaccine Alborz. Primary endpoints: Onset of action and Treatment-emergent adverse events. Started May 2020; status: completed.
02
Drugs
Onabotulinumtoxina + hydrogel
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on IRCT20180515039672N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180515039672N3.